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Abstract
Background: Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that carries a cytotoxic drug (DM1) to
HER2-positive cancer. The target of T-DM1 (HER2) is present also on cancer-derived exosomes. We hypothesized
that exosome-bound T-DM1 may contribute to the activity of T-DM1.
Methods: Exosomes were isolated from the cell culture medium of HER2-positive SKBR-3 and EFM-192A breast cancer
cells, HER2-positive SNU-216 gastric cancer cells, and HER2-negative MCF-7 breast cancer cells by serial centrifugations
including two ultracentrifugations, and treated with T-DM1. T-DM1 not bound to exosomes was removed using HER2-
coated magnetic beads. Exosome samples were analyzed by electron microscopy, flow cytometry and Western
blotting. Binding of T-DM1-containing exosomes to cancer cells and T-DM1 internalization were investigated with
confocal microscopy. Effects of T-DM1-containg exosomes on cancer cells were investigated with the AlamarBlue
cell proliferation assay and the Caspase-Glo 3/7 caspase activation assay.
Results: T-DM1 binds to exosomes derived from HER2-positive cancer cells, but not to exosomes derived from
HER2-negative MCF-7 cells. HER2-positive SKBR-3 cells accumulated T-DM1 after being treated with T-DM1-containg
exosomes, and treatment of SKBR-3 and EFM-192A cells with T-DM1-containing exosomes resulted in growth inhibition
and activation of caspases 3 and/or 7.
Conclusion: T-DM1 binds to exosomes derived from HER2-positive cancer cells, and T-DM1 may be carried to
other cancer cells via exosomes leading to reduced viability of the recipient cells. The results suggest a new mechanism
of action for T-DM1, mediated by exosomes derived from HER2-positive cancer.
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Background
Trastuzumab emtansine (T-DM1, Kadcyla®), an antibody-
drug conjugate (ADC), was designed to deliver the
cytotoxic drug DM1 (a derivative of maytansine) specific-
ally to human epidermal growth factor receptor-2
(HER2)-positive cancer cells. In T-DM1, DM1 molecules
are conjugated to the humanized monoclonal HER2-bind-
ing antibody trastuzumab via a non-reducible thioether
linker SMCC (N-succinimidyl-4-(N-maleimidomethyl)
cyclohexane-1-carboxylate; MCC after conjugation). One
T-DM1 molecule carries an average of 3.5 DM1 molecules
per one molecule of trastuzumab [1]. Binding of T-DM1
to HER2 receptors evokes receptor-mediated endocytosis
of the T-DM1-HER2 complex [2, 3], which is followed by
the proteolytic degradation of the antibody part of T-DM1
in the lysosomes resulting in a release of lysine-MCC-
DM1 into the cytosol [1]. Lysine-MCC-DM1 is a potent
inhibitor of the microtubule assembly leading to cancer
cell death [4, 5]. T-DM1 had substantial anti-cancer effi-
cacy in preclinical models of HER2-positive breast cancer
[1, 6], and after demonstration of its efficacy and safety in
clinical trials [7, 8], the U.S. Food and Drug
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Administration (FDA) approved T-DM1 in 2013 as mono-
therapy for the treatment of patients with HER2-positive
advanced breast cancer who had previously received tras-
tuzumab and a taxane.
Exosomes are small (30 to 200 nm) extracellular vesi-
cles covered by a lipid bilayer membrane. They are gen-
erated by exocytosis of multivesicular bodies [9].
Exosomes may act as cell waste bags, but they may also
have a function in cell-cell communication as their con-
tents (e.g. proteins, lipids, various RNA species and
DNA) can be carried both to the neighboring cells and
distant cells [10–12]. All types of cells, including cancer
cells, secrete exosomes. Exosomes secreted by cancer
cells are called cancer-derived exosomes [9]. Cancer-
derived exosomes have been implicated in the
modulation of cancer growth and metastasis, tumor
angiogenesis, and anti-cancer immunity [13, 14].
HER2, the target protein of T-DM1, may be present
on cancer-derived exosomes [15, 16]. We hypothesized
that the anti-HER2 ADC, T-DM1, might also bind to
cancer-derived exosomes. Since exosomes can carry
their contents into other cells [13], HER2-positive
cancer-derived exosomes might carry the cytotoxic drug
DM1 to distant cells, with potential drug safety and effi-
cacy consequences. Despite the efficacy of T-DM1, most
patients treated with T-DM1 progress, and some HER2-
positive breast cancers are primarily resistant to T-DM1
[7, 8]. The mechanisms of resistance are incompletely
understood [4], and treatment options for patients with
T-DM1-resistant tumors are limited. Therefore, reveal-
ing new mechanisms of action of T-DM1 might have
clinical relevance. In this study we show that T-DM1
binds to exosomes derived from HER2-positive breast and
gastric cancer cells and that HER2-positive breast cancer
cells take up T-DM1 carried on cancer-derived exosomes.
Treatment of HER2-positive breast cancer cells with
T-DM1-exosomes resulted in caspase activation and death
of cancer cells. To our knowledge, this is the first study to
report on the biological effects of exosome-bound anti-
HER2 agents on cancer cell apoptosis.
Methods
Cell lines and antibodies
The human breast cancer cell line EFM-192A was ob-
tained from the German Resource Center for Biological
Material (DSMZ, Braunschweig, Germany), the MCF-7
and SKBR-3 human breast cancer cell lines from the
American Type Culture Collection (ATCC, Manassas,
VA), and the SNU-216 human gastric cancer cell line
from the Korean Cell Line Bank (Seoul, Korea). The
MCF-7 cell line is HER2-negative, whereas SKBR-3,
SNU-216, and EFM-192A overexpress HER2. The
SKBR-3 and EFM-192A cell lines are sensitive to
T-DM1, whereas the SNU-216 and MCF-7 cells are
insensitive [6, 17] (Table 1). The cell lines were cultured
according to recommended specifications. Trastuzumab-
DM1 was purchased from Roche Ltd. (Basel,
Switzerland). Covalent binding of Alexa Fluor 488
(A488) (Invitrogen/Thermo Fisher Scientific, Carlsbad,
United States) to T-DM1 was carried out according to
the manufacturer’s instructions. The dye to protein
labeling ratio was approximately 1:1.5.
Preparation of exosome-depleted cell culture medium
As fetal bovine serum (FBS) contains substantial amounts
of bovine exosomes [18], exosome-depleted medium was
prepared as described previously [19]. In brief, cell culture
medium supplemented with all nutrients and 20% FBS was
centrifuged overnight at 100,000×g at 4 °C. The ultracentri-
fugation was done in polycarbonate tubes (26.3 mL,
Beckman Coulter, Brea, USA) with a 50.2 Ti fixed-angle
rotor (Beckman Coulter) in an Optima XL-80 K Ultracen-
trifuge (Beckman Coulter). The supernatant, which equals
the exosome-depleted medium, was filtered through a 0.
22-μm filter (Merck Millipore, Billerica, USA). The
exosome-depleted medium was diluted with a medium
supplemented with all the nutrients and antibiotics, but no
FBS, in order to reach about 10% FBS concentration. The
exosome-depleted medium was stored at 4 °C until use.
Isolation of exosomes from the cell culture media and
fetal bovine serum (Type A exosomes)
Exosomes were first isolated from the cell culture media
of SKBR-3, SNU-216, and MCF-7 cell lines. The cells were
plated into cell culture flasks with a 175 cm2 surface area,
washed with phosphate-buffered saline (PBS) three times
the next day, and exosome-depleted cell culture medium
was added into the bottles. The medium was harvested
when the cell confluency reached about 90%. The har-
vested medium was purified by serial centrifugations
(1000 × g for 15 min, 2000 × g for 35 min, and 10,000 × g
for 35 min). The exosomes were isolated from the
remaining supernatant by ultracentrifugation (100,000 × g
for 150 min), then suspended in PBS followed by one add-
itional ultracentrifugation (100,000 × g for 150 min). The
pellet was suspended in 300 μL PBS, and then stored in
Protein LoBind tubes (Eppendorf, Hamburg, Germany) at
− 80 °C. All centrifugations were done at 4 °C. The ultra-
centrifugations were done in polycarbonate tubes (26.
3 mL, Beckman Coulter, Brea, USA) with a 50.2 Ti fixed-
angle rotor (Beckman Coulter) in an Optima XL-80 K
Ultracentrifuge (Beckman Coulter) [19]. Since HER2 is
not present on the FBS exosomes [20], we prepared exo-
somes also from cell culture media containing FBS by ser-
ial centrifugations as described above, and used them as a
negative control. Hence forward, exosomes produced
from cancer cells that have not been exposed to T-DM1
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and those present in FBS are called “Type A” exosomes
(Fig. 1a).
Isolation of newly formed exosomes from the SKBR-3 cell
line treated with T-DM1 (Type B exosomes)
To obtain exosomes for testing a hypothesis whether
SKBR-3 cells treated with T-DM1 produce T-DM1-
containing exosomes, we first plated SKBR-3 cells into
culture flasks with a 175 cm2 surface area. When
confluency reached about 75%, the cells were washed
with PBS followed by incubation with either PBS or T-
DM1 (25 μg/mL) or Alexa Fluor 488 (A488)-T-DM1
(25 μg/mL) at 4 °C for 30 min. The cells were then
washed with PBS three times and incubated in an
exosome-depleted cell culture medium overnight. The
medium was harvested and the newly formed exosomes
were purified by serial centrifugations as described
above. We call these newly formed exosomes, secreted
by cancer cells exposed to T-DM1, as “Type B” exo-
somes in the present study (Fig. 1a), to distinguish them
from the exosomes secreted by cells that have not been
exposed to T-DM1, and from the exosomes present in
FBS (Type A exosomes).
Purification of Type A exosomes with HER2-coated
magnetic beads
Type A exosomes were incubated either with PBS or
T-DM1 (25 μg/mL) at 4 °C for 30 min. T-DM1 that was
not bound to exosomes was removed using
HER2-coated magnetic beads. Human HER2 Protein
(Sino Biological, Beijing, China) was coupled to magnetic
Dynabeads using the Dynabeads® Antibody Coupling Kit
Table 1 The cell lines investigated
Cell line Origin HER2 status Reported sensitivity to T-DM1
SKBR-3 Human breast cancer Positive Sensitive (IC50 0.005 μg/mL) [1, 6]
EFM-192A Human breast cancer Positive Sensitive (IC50 0.426 μg/mL) [6]
SNU-216 Human gastric cancer Positive Insensitive (IC50 > 10 μg/mL) [17]
MCF-7 Human breast cancer Negative Insensitive (IC50 > 10 μg/mL) [6]
IC50, half-maximal inhibitory concentration
Fig. 1 Isolation and treatment of Type A and Type B exosomes (a). T-DM1 binds to Type A exosomes prepared from the cell culture medium of
HER2-positive breast and gastric cancer cells. Immuno-electron microscopy images showing MCF-7 exosomes treated with T-DM1 (b), SKBR-3 exosomes
treated with PBS (c), SKBR-3 exosomes treated with T-DM1 (d), and SNU-216 exosomes treated with T-DM1 (e). T-DM1 is present on exosomes derived
from the HER2-positive cell lines (SKBR-3, SNU-216) and treated with T-DM1 (d, e), but not in the controls (b, c). Large arrows point at exosomes, small
arrows at immuno-gold labelled T-DM1
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(Thermo Fisher Scientific, Waltham, USA) according to
the manufacturer’s instructions. 100 μL of the exosome-
containing sample mixed with T-DM1 was incubated
with HER2-coated Dynabeads (286 μL; contains 14.3 μg
HER2 and 2.95 mg Dynabeads). The appropriate amount
of HER2-magnetic beads was determined using T-DM1-
spiked PBS samples (data not shown). During the
incubation, T-DM1 that was not bound to exosomes was
captured by the HER2-coated Dynabeads. A magnetic
field was next applied, and the supernatant was re-
moved. The supernatant contained the exosomes,
whereas the non-exosome bound T-DM1 remained on
the HER2-Dynabeads.
Flow cytometry
After incubation with T-DM1 and extraction of unbound
T-DM1 with HER2-coated Dynabeads, the T-DM1 con-
tent of Type A exosomes was measured using flow cy-
tometry [19, 21]. A volume of 38 μL each sample was
incubated with 3 μL aldehyde/sulfate latex beads (4 μm;
Thermo Fisher Scientific, Waltham, USA) for 15 min at
room temperature (RT). The aldehyde/sulfate latex
beads are hydrophobic with a high density of aldehyde
groups on the bead surface, which enables non-specific
binding of exosomes and proteins to the latex beads.
PBS was then added to the samples to a final volume of
1 mL, and the samples were incubated on a rotator
wheel for 120 min at RT. The samples were then mixed
with 110 μL of 1 M glycine and incubated for 30 min at
RT, washed with PBS, and the beads were suspended
and washed with PBS with 2% bovine serum albumin
(BSA) three times. For staining, the beads were sus-
pended in 100 μL PBS with 2% BSA containing 1 μL
A488-goat anti-human-IgG (A488-GAHIG; Jackson
ImmunoResearch, West Grove, USA) and incubated for
30 min at RT. Then samples were washed with PBS
twice and suspended in 130 μL PBS. Exosomes from the
cell culture medium of the SKBR-3 and SNU-216 cell
lines and treated with PBS were used as the controls to
the exosomes that had been treated with T-DM1. Type
B exosomes isolated from the cell culture medium of
SKBR-3 breast cancer cells treated with A488-T-DM1 or
PBS were prepared similarly, except that 2 μg of purified
exosomes were incubated with 3 μL aldehyde/sulfate
latex beads and these samples were not labeled with
A488-GAHIG. The fluorescence intensity (FI) of A488
was determined using an Accuri C6 Flow Cytometer
(Accuri Cytometers, Inc., Ann Arbor, USA).
Protein quantification
For the total protein content quantification the samples
were mixed with RIPA buffer (Cell Signaling Technol-
ogy, Danvers, USA), incubated for 2 min at RT, and then
mixed with the Bradford Ultra reagent (Novexin,
Cambridge, UK). Serially diluted bovine serum albumin
samples were used as the standard. Absorbance was
measured at 595 nm using a PHERAstar FS plate reader
(BMG Labtech, Ortenberg, Germany). Sample protein
concentration was determined from the standard curve
and the absorbance values of the samples.
Electron microscopy
The samples were prepared for electron microscopy and
imaged as described elsewhere [22] using an immuno-
staining procedure. In brief, after paraformaldehyde fix-
ation, the samples were blocked with 0.5% BSA in 0.1 M
sodium phosphate buffer (pH 7.0) for 10 min RT, incu-
bated with 12 nm colloidal gold conjugated goat-anti-
human-IgG (gold-GAHIG) secondary antibody (Jackson
ImmunoResearch, West Grove, USA) in the same sodium
phosphate buffer for 30 min at RT, washed with the so-
dium phosphate buffer and deionized water, stained with
uranyl acetate, and embedded in a methyl cellulose uranyl
acetate mixture. The samples were viewed using either a
Tecnai 12 (FEI Company, Eindhoven, The Netherlands) or
a Jeol JEM-1400 (Jeol Ltd., Tokyo, Japan) transmission
electron microscope operating at 80 kV.
Western blotting
For Western blotting, 4 μL of Type A exosomes were
mixed with RIPA buffer (Cell Signaling Technology,
Danvers, MA, USA), then with Laemmli sample buffer
containing β-mercaptoethanol (Bio-Rad, Oxford, UK), de-
natured at 95 °C for 5 min, loaded to Mini-PROTEANR
TGX™ 10% gradient SDS-PAGE gels (Bio-Rad, Oxford,
UK), and blotted on Immobilon-P membranes (Millipore,
Bedford, MA, USA). Blocking (1 h, RT) and antibody in-
cubations (the primary antibodies overnight at 4 °C; the
secondary antibodies 1.5 h at RT) were performed in 5%
non-fat powdered milk (Valio, Helsinki, Finland) in TBS
and in TBS with 0.1% Tween-20, respectively. The anti-
human CD63 antibody (EXOAB-CD63A-1; 1:1000) was
purchased from System Biosciences (Palo Alto, USA), and
the anti-bovine CD63 antibody (abx021473; 1:500) from
Abbexa (Cambridge, UK). For detection, horseradish
(HRP)-conjugated secondary antibodies (HRP-conjugated
rabbit anti-mouse IgG, 1:20,000; HRP-conjugated goat
anti-human IgG (for detection of T-DM1), 1:20,000, both
from Jackson ImmunoResearch; and HRP-conjugated goat
anti-rabbit IgG, 1:20,000, System Biosciences) and a 1:2
mixture of SuperSignal™ West Pico Chemiluminescent
Substrate and SuperSignal™ West Femto Maximum Sensi-
tivity Substrate (Thermo Fisher Scientific, Waltham, USA)
were used.
Confocal microscopy
SKBR-3 cells were plated on chambered cover glasses
(Thermo Fisher Scientific, Waltham, USA) and treated
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with 2.5 μL of Type A exosomes, 2 μg of Type B exo-
somes, PBS, or 20 μg/mL of T-DM1. The exosome-
treated cells were incubated overnight, whereas the
PBS-treated and T-DM1-treated cells were incubated for
2 h at 37 °C in a CO2 incubator. The cells were washed
three times with PBS, fixed with 3.5% formaldehyde-
PBS, permeabilized (0.1% Triton X-100 in PBS), washed
with 3% BSA-PBS twice, and incubated with A488-goat
anti-human-IgG (1:100) diluted in 3% BSA-PBS for
20 min at RT. Finally, the cells were washed three times
with PBS and stored in 1% formaldehyde-PBS. The nu-
clei were stained with DAPI (Thermo Fisher Scientific,
Waltham, USA). A Zeiss LSM 780 confocal laser-
scanning microscope (Carl Zeiss, Göttingen, Germany)
was used to image the samples. Fluorescence images
were taken as 1 μm optical sections using a Plan-Apo-
chromat 63 × (numerical aperature, 1.4) oil immersion
objective.
In vitro assays of cell viability and caspase activation
The effects of T-DM1-exosomes on cell viability were
assessed by the AlamarBlue method (Thermo Fisher
Scientific, Waltham, USA). SKBR-3 and EFM-192A cells
were trypsinised and plated in 96-well flat-bottomed tis-
sue culture plates (8000 cells per well). After overnight
culture, the medium was exchanged to a medium con-
taining 2.5 μL of Type A exosomes or 11 μL of Type B
exosomes. As a positive control, cells were treated with
a medium containing 1 μg/mL T-DM1 [6]. The number
of viable cells was assessed after a 96-h incubation
followed by adding the AlamarBlue reagent (Thermo
Fisher Scientific, Waltham, USA). Fluorescence was
measured with excitation at 540 nm and emission at
590 nm using a PHERAstar FS plate reader (BMG
Labtech, Germany). The fluorescence of the samples was
normalized with fluorescence values of the cell culture
media that did not contain cells. The results are pre-
sented as the proportion of viable cells, which was ob-
tained by dividing the fluorescence of the test samples
by the fluorescence of PBS-treated control samples.
To estimate the tendency of breast cancer cells to
undergo apoptosis, caspase activation was assessed using
the Caspase-Glo 3/7 method (Promega, Madison, USA).
The cells were trypsinised and plated in 96-well flat-
bottomed tissue culture plates, 8000 SKBR-3 cells or
EFM-192A cells per well. After overnight culture, the
medium was exchanged to a medium containing 2.5 μL of
Type A exosomes. As a positive control, the cells were
treated with a medium containing 1 μg/mL of T-DM1 [6].
After 96 h of incubation, 100 μL of the medium was trans-
ferred into white-walled 96-well plates, mixed with 100 μL
Caspase-Glo 3/7 reagent, incubated for 30 min at RT, and
the luminescence was recorded using a PHERAstar FS
plate reader (BMG Labtech, Germany). The results are
presented as luminescence units obtained after subtracting
the luminescence value from a blank reaction (without
T-DM1 treatment).
Statistical analysis
The data are expressed as the mean ± standard error
(SE). Groups were compared using the Student’s t test
after verifying that the data passed the test for the nor-
mal distribution. P values ≤0.05 with 2-sided testing
were considered significant.
Results
T-DM1 binds to Type A exosomes derived from HER2-
positive breast and gastric cancer cells
Extracellular vesicles of 30 to 300 nm in diameter (called
here as exosomes) were detected with transmission elec-
tron microscopy in the culture medium of MCF-7,
SKBR-3, and SNU-216 cell lines, and in FBS (Fig. 1,
Additional file 1: Figure S1). At immuno-electron
microscopy, T-DM1 was present on the surface of Type
A exosomes derived from the HER2-positive cell lines
(SKBR-3, SNU-216) and treated with T-DM1, but not on
any of the control Type A exosomes (SKBR-3 or SNU-
216 exosomes treated with PBS, or MCF-7 or FBS exo-
somes treated with T-DM1).
In a flow cytometry analysis, where exosome-bound
T-DM1 was detected by staining it with A488-goat anti-
human IgG, high amounts of T-DM1 were found in Type
A exosomes derived from the culture media of the HER2-
positive cell lines (SKBR-3, SNU-216) and treated with
T-DM1 compared to exosomes from the HER2-negative
cell line MCF-7 or FBS treated with T-DM1, or to SKBR-3
or SNU-216 exosomes treated with PBS (Fig. 2a).
In a Western blot analysis using the human exosome
marker CD63, Type A exosomes were detected in the
culture media of all human cell lines tested. Bovine exo-
somes were detected in FBS with the bovine-specific
antibody against exosome marker CD63 (Fig. 2b). A high
T-DM1 content was found in SKBR-3 exosomes treated
with T-DM1 and a lower content in SNU-216 exosomes
treated with T-DM1. Small amounts of T-DM1 were de-
tected also in two negative controls, in FBS exosomes
and in MCF-7 exosomes treated with T-DM1, suggesting
that some T-DM1 remained in these samples after the
HER2-Dynabead purification.
HER2-positive cells internalize T-DM1 after being treated
with Type A T-DM1-exosomes
We next treated HER2-positive SKBR-3 breast cancer
cells with Type A exosomes to find out whether
exosome-carried T-DM1 may be taken up by the cells.
T-DM1 was used as a positive control, and MCF-7 exo-
somes treated with T-DM1, FBS exosomes treated with
T-DM1, SKBR-3 exosomes treated with PBS, and SNU-
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216 exosomes treated with PBS were used as negative
controls. After treating the cells with either Type A exo-
somes or T-DM1, T-DM1 was stained with Alexa
488-goat anti-human-IgG and the cell nuclei with DAPI,
and the slides were viewed using confocal microscopy.
Cell membrane binding or internalization of T-DM1
could not be detected in any of the negative control
samples (Fig. 3a to f; Additional file 2: Figure S2 panels
A to F), whereas strong cell membrane binding of
T-DM1 and intracellular T-DM1 were visible in SKBR-3
cells treated with unbound T-DM1 used as the positive
control (Fig. 3g to j). Both cell membrane and internal-
ized T-DM1 were also present in SKBR-3 cells that were
treated with SNU-216 exosomes treated with T-DM1, or
with SKBR-3 exosomes treated with T-DM1, although
the amounts of T-DM1 were lower than in the positive
control samples (Fig. 3k to n and o to r).
Type A T-DM1-exosomes reduce viability of HER2-positive
cancer cells
The effects of Type A exosomes on cell viability were
studied in two HER2-positive breast cancer cell lines
that are sensitive to T-DM1, SKBR-3, and EFM-192A
[6]. MCF-7 exosomes treated with T-DM1 were selected
as a reference for efficacy, since some T-DM1 was de-
tected in this sample by Western blotting and flow
cytometry. Treatment with unbound T-DM1 was used
as the positive control. After 96 h of incubation, un-
bound T-DM1 reduced markedly the proportion of sur-
viving cells in both SKBR-3 and EFM-192A cell lines as
compared with MCF-7 exosomes treated with T-DM1
(P < 0.01). SKBR-3 exosomes and SNU-216 exosomes
treated with T-DM1 reduced significantly the viability of
SKBR-3 cells (P < 0.01, and P < 0.05, respectively).
SKBR-3 exosomes treated with T-DM1 reduced signifi-
cantly also the viability of EFM-192A cells (P < 0.01),
while SNU-216 exosomes treated with T-DM1 did not
(Fig. 4a–b).
T-DM1-treated Type A exosomes increase caspase activity
in HER2-positive breast cancer cells
The influence of Type A exosomes on caspase-3 and/or
caspase-7 activation was studied in the HER2-positive
cell lines SKBR-3 and EFM-192A after 96 h incubation
of the cells with Type A exosomes. Efficacy of other
treatments were compared to MCF-7 exosomes treated
with T-DM1. T-DM1 treatment (positive control) re-
sulted in a marked activation of caspase-3 and/or
caspase-7 activity in both cell lines as compared with
MCF-7 exosomes treated with T-DM1 (P < 0.01). SKBR-
3 exosomes treated with T-DM1 increased significantly
caspase-3 and/or caspase-7 activity in both SKBR-3 and
Fig. 2 The T-DM1 and CD63 content of Type A exosomes. T-DM1-treated SKBR-3 and SNU-216 exosomes (red and blue, respectively) have a
higher fluorescence intensity (FI) in flow cytometry indicating a higher T-DM1 content in these exosomes as compared with the control samples
(T-DM1-treated MCF-7 exosomes, pink; T-DM1-treated FBS exosomes, green; PBS-treated SKBR-3 exosomes, orange; PBS-treated SNU-216 exosomes,
black) (a). The human exosome marker protein CD63 is present in the Type A exosomes obtained from the culture media of the human cell lines, and
the bovine CD63 exosome marker in FBS treated with T-DM1 in a Western blot analysis (b). T-DM1 content was high in SKBR-3 cell line-derived
exosomes treated with T-DM1 (B). 55 ng of T-DM1 was used as a positive control (X)
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EFM-192A cells (P < 0.01). Exosomes derived from
SNU-216 cells and treated with T-DM1 increased signifi-
cantly caspase activity in the SKBR-3 cells (P < 0.01), but
not in EFM-192A cells. No change in the caspase activity
was detected when the cells were treated with FBS exo-
somes treated with T-DM1 (Fig. 4c–d).
T-DM1 is present on newly formed exosomes harvested
from the cell culture medium of breast cancer cells
previously treated with T-DM1 (Type B exosomes)
We next investigated the properties of exosomes that were
not directly mixed with T-DM1, but were newly formed
and originated from cells that had been exposed to T-
DM1 (Type B exosomes). In these experiments, SKBR-3
breast cancer cells were first incubated with either PBS or
T-DM1 for 30 min, followed by washing and incubation
in an exosome-depleted cell culture medium overnight.
The exosomes shed into a fresh exosome-depleted culture
medium were then isolated and studied.
In transmission electron microscopy, exosomes with
30 to 300 nm in size were present in the fresh culture
media. Immuno-gold labelled T-DM1 was found on
Type B exosomes harvested from the medium of SKBR-
3 cells that had been treated with T-DM1, but not when
Fig. 3 T-DM1 carried on Type A exosomes may bind to cells and internalize. Confocal microscopy images of HER2-positive SKBR-3 breast cancer
cells treated with Type A exosomes or unbound T-DM1. T-DM1 was stained with Alexa 488-goat anti-human-IgG (A488-GAHIG) and the nuclei
with DAPI. No T-DM1 is detected in SKBR-3 cells when treated with MCF-7 exosomes treated with T-DM1 (a–c) or when treated with SKBR-3 exosomes
treated with PBS (d–f) (negative controls). Treatment of SKBR-3 cells with unbound T-DM1 (positive control) resulted in strong cell membrane staining
(g–i) and internalization of T-DM1 (insert j). Treatment of SKBR-3 cells with SNU-216 exosomes treated with T-DM1 (k–m) or with SKBR-3 exosomes
treated with T-DM1 (o–q) resulted in cell membrane staining, and internalization of some T-DM1 (inserts n and r, respectively). The images were taken
with identical microscope settings
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they had been treated with PBS, showing that SKBR-3
cells dispose T-DM1 on exosomes (Fig. 5a and b). When
the cell culture medium exosome content was measured
with flow cytometry after the cells had been exposed to
either A488-T-DM1 or PBS for 30 min, a higher fluores-
cence intensity was present in the samples obtained
from the medium of T-DM1-treated cells as compared
to PBS-treated cells (Fig. 5c).
In confocal microscopy imaging, SKBR-3 breast cancer
cells showed no staining when treated with exosomes
isolated from a fresh medium of SKBR-3 cells previously
treated with PBS, whereas the cells stained for T-DM1
when they were treated with exosomes obtained from a
fresh medium of SKBR-3 cells that had been previously
exposed to T-DM1 (Fig. 6). Exosomes harvested from
the cell culture medium of SKBR-3 cells that had been
treated with PBS or T-DM1 did not have detectable in-
fluence on the viability of SKBR-3 cells (Fig. 5d).
Discussion
Trastuzumab emtansine (T-DM1) has several proposed
mechanisms of action [4]. Active catabolites of DM1 are
Fig. 4 The influence of Type A T-DM1 exosomes on breast cancer cell viability and caspase activity. The effects of Type A exosomes derived from
MCF-7, SKBR-3, and SNU-216 cell lines, and from FBS, on the viability of SKBR-3 cells (a, c) and EFM-192A cells (b, d) were investigated. Efficacy of
other treatments were compared to MCF exosomes treated with T-DM1. Treatment with unbound T-DM1 was used as a positive control. a, b
Treatment with SKBR-3 exosomes treated with T-DM1 reduced the proportion of surviving cells significantly in both cell lines, and SNU-216 exosomes
treated with T-DM1 reduced the viability of the SKBR-3 cells. c, d T-DM1 (positive control) and SKBR-3 exosomes treated with T-DM1 increased the
caspase-3 and/or caspase-7 activity in both SKBR-3 and EFM-192A cells compared to MCF-7 exosomes treated with T-DM1. c SNU-216 exosomes
treated with T-DM1 increased the caspase activity in the SKBR-3 cell line. **, P < 0.01; *, P < 0.05
Barok et al. BMC Cancer  (2018) 18:504 Page 8 of 12
potent microtubule inhibitors that cause impaired intra-
cellular trafficking and/or cell cycle arrest, which lead to
apoptotic cell death or a mitotic catastrophe [1, 6].
T-DM1 also evokes antibody-dependent cell-mediated
cytotoxicity (ADCC) and inhibits shedding of the extra-
cellular domain of HER2 [6, 23]. The target of T-DM1,
HER2, may be present on cancer-derived exosomes [15,
16], and, in line with the current findings, trastuzumab
may bind to HER2-positive exosomes [24]. We hypothe-
sized that T-DM1 may bind to HER2-expressing cancer-
derived exosomes. Since exosomes can transfer their
contents to both the neighboring cells and distant cells
[10, 12], T-DM1-exosomes might be able to carry the
cytotoxic agent (DM1) into other cells, which might in-
fluence the efficacy and toxicity of T-DM1.
To test this hypothesis, we applied two different strat-
egies for exosome isolation and treatment of cancer cells
with exosomes, each of which could have biological rele-
vance in the tumor microenvironment. First, exosomes
were harvested from the cell culture medium of HER2-
positive breast and gastric cancer cells. The exosomes
were then treated with T-DM1 followed by removal of
the unbound T-DM1 (Type A exosomes). In this model,
T-DM1 binds to cancer-derived exosomes that have
already been secreted into the tumor microenvironment.
We found T-DM1 on exosomes derived from HER2-
positive breast and gastric cancer cells and treated with
T-DM1, and showed that these exosomes can carry
T-DM1 into other cancer cells leading to caspase activa-
tion and cell death. In the second model, cancer cells
were treated with T-DM1, washed, and grown in an
exosome-free culture medium overnight, and we then
isolated the freshly secreted exosomes from the culture
medium (Type B exosomes). In this model, T-DM1 first
needs to bind to HER2 on cancer cell plasma membrane,
be internalized, and then be secreted from the cells into
the cell environment on cancer cell-derived exosomes.
T-DM1 was found to be present also on Type B exo-
somes, and, moreover, these exosomes could also carry
T-DM1 to other cancer cells.
At the first glance, it might seem unnecessary to make
a distinction between Type A and Type B exosomes.
The mechanisms that lead to T-DM1 being a part of the
Type B exosomes are incompletely understood. Exo-
somes are secreted when the intracellular multivesicular
bodies fuse with the plasma membrane, but the exo-
somes have a lipid bilayer which has a different compos-
ition from the plasma membrane [25]. Therefore,
Fig. 5 T-DM1 is excreted from SKBR-3 cells on Type B exosomes. a, b Immuno-electron microscopy images of the exosomes obtained from the
cell culture medium of SKBR-3 cells treated with either PBS or T-DM1. Immuno-gold labelled T-DM1 (small arrows) is detectable on exosomes isolated
from cells exposed to T-DM1 (a), but not when the cells were treated with PBS (b). Large arrows point at exosomes, small arrows at T-DM1. c In flow
cytometry, a higher fluorescent intensity (FI) was detected in exosome samples isolated from the cell culture medium of SKBR-3 cells treated with
A488-T-DM1 (red) as compared to samples isolated from the medium of cells treated with PBS (black). d T-DM1 reduced markedly the growth of
SKBR-3 breast cancer cells (positive control), whereas Type B exosomes secreted into the exosome-depleted growth medium from T-DM1-treated or
PBS-treated SKBR-3 cells did not. **, P < 0.01
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T-DM1 coupled to the plasma membrane may not bind
to exosomes during exosome shedding, but T-DM1
more likely needs first to bind to cell surface HER2, be
internalized and transported into the early lysosomes,
and later into the multivesicular bodies where it be-
comes integrated into the exosomes and becomes shed-
ded. Alternatively, T-DM1 bound to HER2 on the cell
surface could be secreted on microvesicles directly from
the plasma membrane. These could be mechanisms with
which the cells can dispose T-DM1. If unbound T-DM1
is still present in the cell microenvironment at the time
of exosome shedding, it may still bind to Type B exo-
somes. Little is still known about whether the T-DM1
intracellular cycling changes the biological properties of
the exosomes produced after exposure to T-DM1.
The cytotoxic effect of T-DM1 in cells likely depends
on the intracellular concentration of DM1, resulting
from the breakdown of the antibody part of T-DM1 and
the release of DM1 from the lysosomes [4], whereas exo-
somes lack intraexosomal compartments and do not
have acidic pH [26], suggesting that the effect of T-
DM1-exosomes on cancer cells results from T-DM1
bound onto the exosome surface rather that from the
release of DM1 within the exosome. Exosomes with
more HER2 on their surface may have a greater cell
growth inhibitory effect than exosomes with less HER2
expression, since they can carry more T-DM1 into the
recipient cells. SKBR-3 cells express more HER2 than
SNU-216 cells [17], and hence SKBR-3-derived exo-
somes may also express more HER2 than SNU-216-
derived exosomes. We found SKBR-3-derived exosomes
to carry more T-DM1 than exosomes derived from the
SNU-216 cells. This may explain the observation that
Type A T-DM1-exosomes derived from SKBR-3 cells
had a greater growth inhibitory effect on both SKBR-3
and EFM-192A breast cancer cells than Type A T-DM1-
exosomes derived from SNU-216 cells. Similarly, the
treatment with Type A T-DM1-exosomes derived from
SKBR-3 cells resulted in a more substantial caspase acti-
vation in both SKBR-3 and EFM-192A breast cancer
cells than Type A T-DM1-exosomes derived from
SNU-216 cells. Since we incubated Type A exosomes
with a relatively high concentration of T-DM1 (25 μg/
mL), the T-DM1 binding sites of the existing exosomes
likely became saturated, which might not have been the
case with the newly formed (Type B) exosomes, which
Fig. 6 Confocal microscopy images of HER2-positive SKBR-3 breast cancer cells treated with Type B exosomes. a–c No T-DM1 is detected on the
SKBR-3 cells treated with exosomes harvested from fresh cell culture medium of PBS-treated SKBR-3 cells (negative control). d–f Intense membranous
staining is present when the cells were treated with T-DM1 (positive control). g–i T-DM1 is present on cells treated with exosomes obtained from fresh
cell culture medium of T-DM1-treated cells. The images were taken with identical microscope settings
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could in part explain why Type B exosomes did not have
a detectable effect on cancer cell growth unlike the Type
A exosomes.
Exosomes may carry mRNA, miRNA, DNA, and pro-
teins to distant cells, which is a type of cell-cell commu-
nication [10–12]. We found that exosomes secreted
from cancer cells may pick up molecules (such as
T-DM1) in the extracellular environment and deliver
them into other cells, and the molecules picked up may
influence the function of the recipient cells (such as
T-DM1 caused growth inhibition and increased caspase
activation). This finding suggests that exosomes may
regulate cell-cell communication not only by carrying
biologically active molecules originating from the intra-
cellular space, but also by carrying molecules originating
from the extracellular microenvironment.
The mechanisms of cell uptake of exosomes and their
cargo are not well understood. Uptake can happen via
the fusion of exosome and the recipient cell plasma
membranes, through endocytosis, macropinocytosis, and
phagocytosis [27, 28]. Cancer-derived exosomes can
enter the circulation and deliver their contents to distant
cells [10, 12]. Therefore, T-DM1-exosomes might be able
to carry DM1 into distant cells, which could potentially
influence even the adverse effects of T-DM1. This hy-
pothesis warrants further study.
Conclusion
In conclusion, we showed that T-DM1 can bind to exo-
somes derived from HER2-positive breast cancer cells
and gastric cancer cells. In addition, T-DM1 can be de-
livered on exosomes to other cancer cells, which may re-
sult in growth inhibition and apoptotic death of the
recipient HER2-positive cancer cells. The results suggest
a new, exosome-mediated mechanism of action for
T-DM1 that might influence the efficacy of T-DM1. The
present observations warrant further study both in in
vivo models and in the clinical setting.
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Abbreviations
A488: Alexa Fluor 488; ADCC: Antibody-dependent cellular cytotoxicity;
BSA: Bovine serum albumin; DM1: Derivative of maytansine; FBS: Fetal bovine
serum; FDA: Food and drug administration; FI: Fluorescence intensity;
GAHIG: Goat anti-human immunoglobulin; HER2: Human epidermal growth
factor receptor-2; PBS: Phosphate-buffered saline; RT: Room temperature;
SMCC: N-succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate;
T-DM1: Trastuzumab-emtansine
Acknowledgements
We thank technician Marko Salmikangas for skillful help in performing the
experiments, the EV Core, University of Helsinki, for the electron microscopy
work, and the Electron Microscopy Unit of the Institute of Biotechnology,
University of Helsinki, for providing the facilities.
Funding
Cancer Society of Finland, Sigrid Juselius Foundation, Jane and Aatos Erkko
Foundation, Academy of Finland, Research Funds of Helsinki University
Hospital, SalWe Research Program Personalized Diagnostics and Care (GET IT
DONE, TEKES) grant 3986/31/2013, National Research, Development and
Innovation Office, Hungary (GINOP-2.3.2-15-2016-00020, and GINOP-2.3.2-15-
2016-00050). The funding body had no role in the design of the study and
collection, analysis, and interpretation of data and in writing the manuscript.
Availability of data and materials
All data supporting the findings in this study are included within the manuscript
and the supplement figures. The raw data used for analysis would be available
from the corresponding author on request.
Authors’ contributions
MB conceived the hypothesis, designed the experimental approach, performed
the experimental work, analyzed data, coordinated the project and wrote the
manuscript. MP discussed the hypothesis, did electron microscopy, analyzed
the data, contributed to the data interpretation and discussion. GV, JS and JI
discussed the hypothesis, contributed to data interpretation and discussion. HJ
led the project, discussed the hypothesis, designed the experimental approach,
interpreted data and wrote the manuscript. All authors read and approved the
final manuscript.
Ethics approval and consent to participate
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Author details
1Laboratory of Molecular Oncology, University of Helsinki, Biomedicum
Helsinki, Haartmaninkatu 8, FIN-00290 Helsinki, Finland. 2Institute for
Molecular Medicine FIMM and EV Core, University of Helsinki, Helsinki,
Finland. 3Department of Biophysics and Cell Biology, Faculty of Medicine,
University of Debrecen, Debrecen 4032, Hungary. 4MTA-DE Cell Biology and
Signaling Research Group, Faculty of Medicine, University of Debrecen,
Debrecen 4032, Hungary. 5Laboratory of Cancer Biology, Medical Faculty,
University of Tampere, Biokatu 6, 33014 Tampere, Finland. 6Department of
Oncology, Helsinki University Hospital and University of Helsinki,
Haartmaninkatu 4, FIN-00029 Helsinki, Finland.
Received: 22 November 2017 Accepted: 22 April 2018
References
1. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al.
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-
cytotoxic drug conjugate. Cancer Res. 2008;68(22):9280–90.
2. Ritchie M, Tchistiakova L, Scott N. Implications of receptor-mediated
endocytosis and intracellular trafficking dynamics in the development of
antibody drug conjugates. MAbs. 2013;5:13–21.
3. Kovtun Y, Goldmacher V. Cell killing by antibody-drug conjugates. Cancer
Lett. 2007;255:232–40.
4. Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action
and drug resistance. Breast Cancer Res. 2014;16(2):209.
5. Chari R. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Acc Chem Res. 2008;41:98–107.
Barok et al. BMC Cancer  (2018) 18:504 Page 11 of 12
6. Barok M, Tanner M, Koninki K, Isola J. Trastuzumab-DM1 causes tumour
growth inhibition by mitotic catastrophe in trastuzumab-resistant breast
cancer cells in vivo. Breast Cancer Res. 2011;13(2):R46.
7. Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, et al. Phase II
randomized study of trastuzumab emtansine versus trastuzumab plus
docetaxel in patients with human epidermal growth factor receptor 2-
positive metastatic breast cancer. J Clin Oncol. 2013;31(9):1157–63.
8. Verma S, Miles D, Gianni L, Krop I, Welslau M, Baselga J, et al. Trastuzumab
emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;
367:1783–91.
9. Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and
function. Nat Rev Immunol. 2002;2(8):569–79.
10. Al-Nedawi K, Meehan B, Rak J. Microvesicles: messengers and mediators of
tumor progression. Cell Cycle. 2009;8(13):2014–8.
11. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-
mediated transfer of mRNAs and microRNAs is a novel mechanism of
genetic exchange between cells. Nat Cell Biol. 2007;9(6):654–9.
12. Ratajczak J, Wysoczynski M, Hayek F, Janowska-Wieczorek A, Ratajczak MZ.
Membrane-derived microvesicles: important and underappreciated
mediators of cell-to-cell communication. Leukemia. 2006;20(9):1487–95.
13. Kalluri R. The biology and function of exosomes in cancer. J Clin Invest.
2016;126(4):1208–15.
14. Kosaka N, Yoshioka Y, Fujita Y, Ochiya T. Versatile roles of extracellular
vesicles in cancer. J Clin Invest. 2016;126(4):1163–72.
15. Koga K, Matsumoto K, Akiyoshi T, Kubo M, Yamanaka N, Tasaki A, et al.
Purification, characterization and biological significance of tumor-derived
exosomes. Anticancer Res. 2005;25(6A):3703–7.
16. Andre F, Schartz NE, Movassagh M, Flament C, Pautier P. Morice P, et al;
malignant effusions and immunogenic tumour-derived exosomes. Lancet.
2002;360(9329):295–305.
17. Barok M, Tanner M, Koninki K, Isola J. Trastuzumab-DM1 is highly effective in
preclinical models of HER2-positive gastric cancer. Cancer Lett. 2011;306:
171–9.
18. Shelke GV, Lasser C, Gho YS, Lotvall J. Importance of exosome depletion
protocols to eliminate functional and RNA-containing extracellular vesicles
from fetal bovine serum. J Extracell Vesicles. 2014;3. https://doi.org/10.3402/
jev.v3.24783.
19. Thery C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of
exosomes from cell culture supernatants and biological fluids. Curr Protoc
Cell Biol. 2006;Chapter 3:Unit 3.22.
20. Ochieng J, Pratap S, Khatua AK, Sakwe AM. Anchorage-independent growth
of breast carcinoma cells is mediated by serum exosomes. Exp Cell Res.
2009;315(11):1875–88.
21. El-Andaloussi S, Lee Y, Lakhal-Littleton S, Li J, Seow Y, Gardiner C, et al.
Exosome-mediated delivery of siRNA in vitro and in vivo. Nat Protoc. 2012;
7(12):2112–26.
22. Puhka M, Nordberg ME, Valkonen S, Rannikko A, Kallioniemi O, Siljander P,
et al. KeepEX, a simple dilution protocol for improving extracellular vesicle
yields from urine. Eur J Pharm Sci. 2017;15(98):30–9.
23. Junttila T, Li G, Parsons K, Phillips G, Sliwkowski M. Trastuzumab-DM1 (T-
DM1) retains all the mechanisms of action of trastuzumab and efficiently
inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res
Treat. 2010;128:347–56.
24. Ciravolo V, Huber V, Ghedini GC, Venturelli E, Bianchi F, Campiglio M, et al.
Potential role of HER2-overexpressing exosomes in countering trastuzumab-
based therapy. J Cell Physiol. 2012;227(2):658–67.
25. Kowal J, Tkach M, Thery C. Biogenesis and secretion of exosomes. Curr Opin
Cell Biol. 2014;29:116–25.
26. Nakase I, Futaki S. Combined treatment with a pH-sensitive fusogenic
peptide and cationic lipids achieves enhanced cytosolic delivery of
exosomes. Sci Rep. 2015;5:10112.
27. Mulcahy LA, Pink RC, Carter DRF. Routes and mechanisms of extracellular
vesicle uptake. J Extracell Vesicles. 2014;3. https://doi.org/10.3402/jev.v3.
24641.
28. Xu R, Greening DW, Zhu H-J, Takahashi N, Simpson RJ. Extracellular vesicle
isolation and characterization: toward clinical application. J Clin Invest. 2016;
126(4):1152–62.
Barok et al. BMC Cancer  (2018) 18:504 Page 12 of 12
